Document:

EX-10.8(C)

 Exhibit 10.8(c) 

THORNE HEALTHTECH, INC. 

CHANGE IN CONTROL SEVERANCE AGREEMENT 

This Change in Control Severance Agreement (the “Agreement”) is made between Thorne HealthTech, Inc. (the
“Company”) and Thomas P. McKenna (the “Executive”), effective as of                     , 2021 (the
“Effective Date”). 
 This Agreement provides certain protections to the Executive in connection with a change in control
of the Company or in connection with the involuntary termination of the Executive’s employment under the circumstances described in this Agreement. Certain capitalized terms are defined in Section 7 to the extent not otherwise defined in
other Sections of the Agreement. 
 The Company and the Executive agree as follows: 

1. Term of Agreement. This Agreement will terminate upon the date that all of the obligations of the parties hereto with respect to
this Agreement have been satisfied. 
 2. At-Will Employment. The Company and the Executive
acknowledge that the Executive’s employment is and will continue to be at-will, as defined under applicable law. 

3. Severance Benefits. 

(a) Qualifying Non-CIC Termination. In the event of a Qualifying
Non-CIC Termination (as defined below), and subject to Sections 5 and 6, the Executive will be eligible to receive the following from the Company: 

(i) Salary Severance. A single, lump sum payment equal to nine (9) months of the Executive’s Salary (as defined below), less
applicable withholdings. 
 (ii) COBRA Coverage. Subject to Section 3(d), the Company will pay the premiums for coverage under
COBRA (as defined below) for the Executive and the Executive’s eligible dependents, if any, at the rates then in effect, subject to any subsequent changes in rates that are generally applicable to the Company’s active employees (the
“COBRA Coverage”), until the earliest of (A) a period of nine (9) months from the date of the Executive’s termination of employment, (B) the date upon which the Executive (and the Executive’s eligible
dependents, as applicable) becomes covered under similar plans, or (C) the date upon which the Executive ceases to be eligible for coverage under COBRA. 

(b) Qualifying CIC Termination. In the event of a Qualifying CIC Termination (as defined below), and subject to Sections 5 and 6,
the Executive will be eligible to receive the following from the Company: 
 (i) Salary Severance. A single, lump sum payment equal
to twelve (12) months of the Executive’s Salary, less applicable withholdings. 

 (ii) Bonus Severance. A single, lump sum payment equal to one hundred percent (100%)
of the Executive’s target annual bonus as in effect for the fiscal year in which the Qualifying CIC Termination occurs, less applicable withholdings. 

(iii) COBRA Coverage. Subject to Section 3(d), the Company will provide COBRA Coverage until the earliest of (A) a period of
twelve (12) months from the date of the Executive’s termination of employment, (B) the date upon which the Executive (and the Executive’s eligible dependents, as applicable) becomes covered under similar plans, or (C) the
date upon which the Executive ceases to be eligible for coverage under COBRA. 
 (iv) Equity Vesting. Vesting acceleration (and
exercisability, as applicable) as to one hundred percent (100%) of the then-unvested shares subject to each of the Company equity awards granted to the Executive that is outstanding as of the date of the Qualifying Termination (each, an
“Equity Award”). In the case of an Equity Award that is subject to performance-based vesting, unless otherwise specified in the applicable Equity Award agreement governing the Equity Award, all performance goals and other vesting
criteria will be deemed achieved at one hundred percent (100%) of target levels. For the avoidance of doubt, in the event of the Executive’s Qualifying Pre-CIC Termination (as defined below), any then
outstanding Equity Awards will remain outstanding until the earlier of (x) three (3) months following the Qualifying Termination or (y) the occurrence of a Change in Control, solely so that any benefits due on a Qualifying Pre-CIC Termination can be provided if a Change in Control occurs within three (3) months following the Qualifying Termination (provided that in no event will the Executive’s stock options or similar
Equity Awards remain outstanding beyond the Equity Award’s maximum term to expiration). If no Change in Control occurs within three (3) months following a Qualifying Termination, any unvested portion of the Executive’s Equity Awards
automatically and permanently will be forfeited on the date three (3) months following the date of the Qualifying Termination without having vested. 

(c) Termination Other Than a Qualifying Termination. If the termination of the Executive’s employment with the Company Group (as
defined below) is not a Qualifying Termination, then the Executive will not be entitled to receive the severance payments or other benefits specified in this Agreement. 

(d) Conditions to Receipt of COBRA Coverage. The Executive’s receipt of COBRA Coverage is subject to the Executive electing COBRA
continuation coverage within the time period prescribed pursuant to COBRA for the Executive and the Executive’s eligible dependents, if any. If the Company determines in its sole discretion that it cannot provide the COBRA Coverage without
potentially violating, or being subject to an excise tax under, applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then in lieu of any COBRA Coverage, the Company will provide to the Executive a
taxable monthly payment payable on the last day of a given month, in an amount equal to the monthly COBRA premium that the Executive would be required to pay to continue his or her group health coverage in effect on the date of his or her Qualifying
Termination (which amount will be based on the premium rates applicable for the first month of COBRA Coverage for the Executive and any of eligible dependents of the Executive) (each, a “COBRA Replacement Payment”), which COBRA
Replacement Payments will be made regardless of whether the Executive elects COBRA continuation coverage 

  
 2 

 
and will end on the earlier of (x) the date upon which the Executive obtains other employment or(y) the date the Company has paid an amount totaling the number of COBRA Replacement Payments
equal to the number of months in the applicable COBRA Coverage period. For the avoidance of doubt, the COBRA Replacement Payments may be used for any purpose, including, but not limited, to continuation coverage under COBRA, and will be subject to
any applicable withholdings. Notwithstanding anything to the contrary under this Agreement, if the Company determines in its sole discretion at any time that it cannot provide the COBRA Replacement Payments without violating applicable law
(including, without limitation, Section 2716 of the Public Health Service Act), the Executive will not receive the COBRA Replacement Payments or any further COBRA Coverage. 

(e) Non-Duplication of Payment or Benefits. For purposes of clarity, in the event of a Qualifying
Pre-CIC Termination, any severance payments and benefits to be provided to the Executive under Section 3(b) will be reduced by any amounts that already were provided to the Executive under
Section 3(a). Notwithstanding any provision of this Agreement to the contrary, if the Executive is entitled to any cash severance, continued health coverage benefits, or vesting acceleration of any Equity Awards (other than under this
Agreement) by operation of applicable law or under a plan, policy, contract, or arrangement sponsored by or to which any member of the Company Group is a party in connection with the Executive’s separation (“Other Benefits”),
then the corresponding severance payments and benefits under this Agreement will be reduced by the amount of Other Benefits paid or provided to the Executive. 

(f) Death of the Executive. In the event of the Executive’s death before all payments or benefits the Executive is entitled to
receive under this Agreement have been provided, the unpaid amounts will be provided to the Executive’s designated beneficiary, if living, or otherwise to the Executive’s personal representative in a single lump sum as soon as possible
following the Executive’s death. 
 (g) Transfer Between Members of the Company Group. For purposes of this Agreement, if the
Executive is involuntarily transferred from one member of the Company Group to another, the transfer will not be a termination without Cause but may give the Executive the ability to resign for Good Reason. 

(h) Exclusive Remedy. In the event of a termination of the Executive’s employment with the Company Group, the provisions of this
Agreement are intended to be and are exclusive and in lieu of any other rights or remedies to which the Executive may otherwise be entitled, whether at law, tort or contract, or in equity. The Executive will be entitled to no benefits, compensation
or other payments or rights upon termination of employment other than those benefits expressly set forth in this Agreement. 
 4. Accrued
Compensation. On any termination of the Executive’s employment with the Company Group, the Executive will be entitled to receive all accrued but unpaid vacation, expense reimbursements, wages, and other benefits due to the Executive under
any Company-provided plans, policies, and arrangements. For avoidance of doubt, receipt of accrued compensation is not subject to the Release Requirement discussed in Section 5(a). 

  
 3 

 5. Conditions to Receipt of Severance. 

(a) Separation Agreement and Release of Claims. The Executive’s receipt of any severance payments or benefits upon the
Executive’s Qualifying Termination under Section 3 is subject to the Executive signing and not revoking the Company’s then-standard separation agreement and release of claims (which may include an agreement not to disparage any member
of the Company Group, non-solicit provisions, an agreement to assist in any litigation matters, and other standard terms and conditions) (the “Release” and that requirement, the
“Release Requirement”), which must become effective and irrevocable no later than the sixtieth (60th) day following the date of the Executive’s Qualifying Termination (the
“Release Deadline Date”). If the Release does not become effective and irrevocable by the Release Deadline Date, the Executive will forfeit any right to the severance payments or benefits under Section 3. 

(b) Payment Timing. Any lump sum salary or bonus payments under Sections 3(a) and 3(b) will be provided on the first regularly
scheduled payroll date of the Company following the date the Release becomes effective and irrevocable (the “Severance Start Date”), subject to any delay required by Section 5(d) below. Any taxable installments of any
COBRA-related severance benefits that otherwise would have been made to the Executive on or before the Severance Start Date will be paid on the Severance Start Date, and any remaining installments thereafter will be provided as specified in this
Agreement. Subject to Section 5(d), any restricted stock units, performance shares, performance units, and/or similar full value awards that accelerate vesting under Section 3(b) will be settled (x) within ten (10) days following
the date the Release becomes effective and irrevocable, or (y) if later, in the event of a Qualifying Pre-CIC Termination, on the date of the Change in Control.

(c) Return of Company Property. The Executive’s receipt of any severance payments or benefits upon the Executive’s Qualifying
Termination under Section 3 is subject to the Executive having returned all documents and other property provided to the Executive by any member of the Company Group (with the exception of a copy of the Company employee handbook and personnel
documents specifically relating to the Executive), developed or obtained by the Executive in connection with his or her employment with the Company Group, or otherwise belonging to the Company Group, by no later than ten (10) days following the
date of the Qualifying Termination. 
 (d) Section 409A. The Company intends that all payments and benefits provided under this
Agreement or otherwise are exempt from, or comply with, the requirements of Section 409A of the Code (as defined below) and any guidance promulgated under Section 409A of the Code (collectively,
“Section 409A”) so that none of the payments or benefits will be subject to the additional tax imposed under Section 409A, and any ambiguities in this Agreement will be interpreted in accordance with this
intent. No payment or benefits to be paid to the Executive, if any such payments or benefits, under this Agreement or otherwise, when considered together with any other severance payments or separation benefits that are considered deferred
compensation under Section 409A (together, the “Deferred Payments”) will be paid or otherwise provided until the Executive has a “separation from service” within the meaning of Section 409A. If, at the time of
the Executive’s termination of employment, the Executive is a “specified employee” within the meaning of Section 409A, then the payment of the Deferred Payments will be delayed to the extent necessary

  
 4 

 
to avoid the imposition of the additional tax imposed under Section 409A, which generally means that the Executive will receive payment on the first payroll date that occurs on or after the
date that is six (6) months and one (1) day following the Executive’s termination of employment. The Company reserves the right to amend this Agreement as it considers necessary or advisable, in its sole discretion and without the
consent of the Executive or the consent of any other individual, to comply with any provision required to avoid the imposition of the additional tax imposed under Section 409A or to otherwise avoid income recognition under Section 409A
prior to the actual payment of any benefits or imposition of any additional tax. Each payment, installment, and benefit payable under this Agreement is intended to constitute a separate payment for purposes of U.S. Treasury Regulation Section 1.409A-2(b)(2). In no event will any member of the Company Group reimburse, indemnify, or hold harmless the Executive for any taxes, penalties and interest that may be imposed, or other costs that may
be incurred, as a result of Section 409A. 
 (e) Resignation of Officer and Director Positions. The Executive’s receipt of
any severance payments or benefits upon the Executive’s Qualifying Termination under Section 3 is subject to the Executive having resigned from all officer and director positions with all members of the Company Group and the Executive
executing any documents the Company may require in connection with the same. 
 6. Limitation on Payments. 

(a) Reduction of Severance Benefits. If any payment or benefit that the Executive would receive from any Company Group member or
any other party whether in connection with the provisions in this Agreement or otherwise (the “Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and
(ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Payment will be equal to the Best Results Amount. The “Best Results Amount” will be
either (x) the full amount of the Payment or (y) a lesser amount that would result in no portion of the Payment being subject to the Excise Tax, whichever of those amounts, taking into account the applicable federal, state and local
employment taxes, income taxes and the Excise Tax, results in the Executive’s receipt, on an after-tax basis, of the greater amount. If a reduction in payments or benefits constituting parachute payments
is necessary so that the Payment equals the Best Results Amount, reduction will occur in the following order: (A) reduction of cash payments in reverse chronological order (that is, the cash payment owed on the latest date following the
occurrence of the event triggering the excise tax will be the first cash payment to be reduced); (B) cancellation of Equity Awards that were granted “contingent on a change in ownership or control” within the meaning of
Section 280G of the Code in the reverse order of date of grant of the awards (that is, the most recently granted Equity Awards will be cancelled first); (C) reduction of the accelerated vesting of Equity Awards in the reverse order of date
of grant of the awards (that is, the vesting of the most recently granted Equity Awards will be cancelled first); and (D) reduction of employee benefits in reverse chronological order (that is, the benefit owed on the latest date following the
occurrence of the event triggering the excise tax will be the first benefit to be reduced). In no event will the Executive have any discretion with respect to the ordering of Payment reductions. The Executive will be solely responsible for the
payment of all personal tax liability that is incurred as a result of the payments and benefits received under this Agreement, and the Executive will not be reimbursed, indemnified, or held harmless by any member of the Company Group for any of
those payments of personal tax liability. 

  
 5 

 (b) Determination of Excise Tax Liability. Unless the Company and the
Executive otherwise agree in writing, the Company will select a professional services firm (the “Firm”) to make all determinations required under this Section 6, which determinations will be conclusive and binding upon the
Executive and the Company for all purposes. For purposes of making the calculations required by this Section 6, the Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith
interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and the Executive will furnish to the Firm such information and documents as the Firm reasonably may request in order to make determinations under this
Section 6. The Company will bear the costs and make all payments for the Firm’s services in connection with any calculations contemplated by this Section 6. The Company will have no liability to the Executive for the
determinations of the Firm. 
 7. Definitions. The following terms referred to in this Agreement will have the following meanings:

 (a) “Board” means the Company’s Board of Directors. 

(b) “Cause” means (i) the Executive’s willful and repeated failure, in the reasonable judgment of the Board, to
substantially perform his or her assigned duties or responsibility as an employee as directed or assigned by the Chief Executive Officer (other than the Executive’s failure resulting from a Disability); (ii) the Executive engaging in
intentional illegal conduct that was or is materially injurious to the Company Group or its affiliates; (iii) the Executive’s knowing violation of a federal or state law or regulation directly or indirectly applicable to the business of
the Company Group or its affiliates, which violation was or is reasonably likely to be injurious to the Company Group or its affiliates; (iv) the Executive’s material breach of the terms of any confidentiality agreement or invention
assignment agreement between the Executive and the Company Group (or any affiliate); or (v) the Executive being convicted of, or entering a plea of guilty or nolo contendere to, a felony or committing any act of moral turpitude, dishonesty, or
fraud against, or the misappropriation of material property belonging to, the Company Group or its affiliates. The foregoing definition does not in any way limit the Company’s ability to terminate the Executive’s employment at any time,
and the term “Company” will be interpreted to include any subsidiary, parent, affiliate, or any successor thereto, if appropriate. 

(c) “Change in Control” means the occurrence of any of the following events: 

(i) A change in the ownership of the Company which occurs on the date that any one person, or more than one person acting as a group
(“Person”), acquires ownership of the stock of the Company that, with the stock held by such Person, constitutes more than fifty percent (50%) of the total voting power of the stock of the Company; provided, that for this
subsection, the acquisition of additional stock by any one Person, who prior to such acquisition is considered to own more than fifty percent (50%) of the total voting power of the stock of the Company will not be considered a Change in Control
and provided, further, that any change in the ownership of the stock of the Company as a result of a private financing of the Company that is 

  
 6 

 
approved by the Board also will not be considered a Change in Control. Further, if the stockholders of the Company immediately before such change in ownership continue to retain immediately after
the change in ownership, in substantially the same proportions as their ownership of shares of the Company’s voting stock immediately prior to the change in ownership, direct or indirect beneficial ownership of fifty percent (50%) or more of
the total voting power of the stock of the Company or of the ultimate parent entity of the Company, such event shall not be considered a Change in Control under this Section 7(c)(i). For this purpose, indirect beneficial ownership shall
include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities which own the Company, as the case may be, either directly or through one or more subsidiary
corporations or other business entities; or 
 (ii) A change in the effective control of the Company which occurs on the date a majority of
members of the Board is replaced during any twelve (12)-month period by members of the Board whose appointment or election is not endorsed by a majority of the members of the Board prior to the appointment or election. For purposes of this
Section 7(c)(ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control; or 

(iii) A change in the ownership of a substantial portion of the Company’s assets which occurs on the date that any Person acquires (or
has acquired during the twelve (12)-month period ending on the date of the most recent acquisition by such Person or Persons) assets from the Company that have a total gross fair market value equal to or more than fifty percent (50%) of
the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions; provided, that for this Section 7(c)(iii), the following will not constitute a change in the ownership of a substantial
portion of the Company’s assets: 
 (1) a transfer to an entity controlled by the Company’s stockholders immediately after the
transfer, or 
 (2) a transfer of assets by the Company to: 

(A) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company’s stock,

 (B) an entity, fifty percent (50%) or more of the total value or voting power of which is owned, directly or indirectly, by the
Company, 
 (C) a Person, that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power of all the
outstanding stock of the Company, or 
 (D) an entity, at least fifty percent (50%) of the total value or voting power of which is
owned, directly or indirectly, by a Person described in Section 7(c)(iii)(2)(A) to Section 7(c)(iii)(2)(C). 
 For this
definition, gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets. 

  
 7 

 For purposes of this Section 7(c), persons will be considered to be acting as a group
if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. For the avoidance of doubt, wholly-owned subsidiaries of the Company shall not be
considered “Persons” for purposes of this Section 7(c). 
 (iv) A transaction will not be a Change in Control: 

(1) unless the transaction qualifies as a change in control event within the meaning of Code Section 409A; or 

(2) if its primary purpose is to (1) change the jurisdiction of the Company’s incorporation, or (2) create a holding company
owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transaction. 

(d) “Change in Control Period” means the period beginning three (3) months prior to a Change in Control and ending
twelve (12) months following a Change in Control. 
 (e) “COBRA” means the Consolidated Omnibus Budget Reconciliation
Act of 1985, as amended. 
 (f) “Code” means the Internal Revenue Code of 1986, as amended. 

(g) “Company Group” means the Company and its subsidiaries. 

(h) “Disability” means a total and permanent disability as defined in Section 22(e)(3) of the Code. 

(i) “Good Reason” means the Executive’s resignation due to the occurrence of any of the following conditions
which occurs without the Executive’s written consent, provided that the requirements regarding advance notice and an opportunity to cure set forth below are satisfied: (i) a material reduction in the Executive’s Salary, which the
parties agree is a reduction of at least ten percent (10%) of the Executive’s Salary; (ii) a material reduction of the Executive’s duties, authorities, or responsibilities relative to the Executive’s duties, authorities, or
responsibilities in effect immediately prior to the reduction, including where such material reduction results solely by virtue of the Company being acquired and made part of a larger entity (as, for example, when the Chief Financial Officer of the
Company remains as such following a Change in Control but is not made the Chief Financial Officer of the acquiring corporation); or (iii) a change by more than fifty (50) miles in the geographic location at which the Executive must perform
services; provided, however, that no condition described herein will constitute “Good Reason” for purposes of this Agreement unless (1) the Executive will have first provided written notice to the Board of the existence of the
condition within ninety (90) days of the initial existence of such Good Reason condition; (2) the Board will have failed to remedy the condition within thirty (30) days following the receipt of such notice (the “Cure
Period”); (3) the Executive must cooperate in good faith with any efforts by the Company to remedy the Good Reason condition; (4) the Good Reason condition must continue to exist upon completion of the Cure Period; and (5) the
date of termination of employment occurs no more than thirty (30) days after the end of the Cure Period. In no instance will a termination by the Executive be deemed to be for Good Reason for purposes of this Agreement if it becomes effective
more than twelve (12) months following the initial existence of the Good Reason condition. 

  
 8 

 (j) “Qualifying Pre-CIC
Termination” means a Qualifying CIC Termination that occurs prior to the date of the Change in Control. 
 (k) “Qualifying
Termination” means a termination of the Executive’s employment either (i) by a Company Group member without Cause and other than by reason of the Executive’s death or Disability, or (ii) by the Executive for Good Reason,
in either case, during the Change in Control Period (a “Qualifying CIC Termination”) or outside of the Change in Control Period (a “Qualifying Non-CIC Termination”). 

(l) “Salary” means the Executive’s rate of base salary as in effect immediately prior to the Executive’s Qualifying
Termination (or if the termination is due to a resignation for Good Reason based on a material reduction in base salary, then the Executive’s rate of base salary in effect immediately prior to the reduction) or, if the Executive’s
Qualifying Termination is a Qualifying CIC Termination and the amount is greater, at the level in effect immediately prior to the Change in Control. 

8. Successors. This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors, and legal representatives
of the Executive upon the Executive’s death, and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose,
“successor” means any person, firm, corporation, or other business entity which at any time, whether by purchase, merger, or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. None
of the rights of the Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution. Any other attempted assignment, transfer, conveyance, or
other disposition of the Executive’s right to compensation or other benefits will be null and void. 
 9. Notice. 

(a) General. All notices and other communications required or permitted under this Agreement will be in writing and will be effectively
given (i) upon actual delivery to the party to be notified; (ii) upon transmission by email; (iii) twenty-four (24) hours after confirmed facsimile transmission; (iv) one (1)
business day after deposit with a recognized overnight courier; or (v) three (3) business days after deposit with the U.S. Postal Service by first class certified or registered mail, return receipt requested, postage prepaid, addressed
(A) if to the Executive, at the address the Executive will have most recently furnished to the Company in writing, (B) if to the Company, at the following address: 

Thorne HealthTech, Inc. 
 152
West 57th Street, 10th Floor 
 New York, New York 10019 

Attention: Chief Executive Officer 

  
 9 

 (b) Notice of Termination. Any termination by a Company Group member for Cause will
be communicated by a notice of termination to the Executive, and any termination by the Executive for Good Reason will be communicated by a notice of termination to the Company, in each case given in accordance with Section 9(a) of this
Agreement. The notice will indicate the specific termination provision in this Agreement relied upon, will set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination under the provision so indicated, and
will specify the termination date (which will be not more than thirty (30) days after the later of (i) the giving of the notice, or (ii) the end of any applicable cure period). 

10. Resignation. The termination of the Executive’s employment for any reason will also constitute, without any further required
action by the Executive, the Executive’s voluntary resignation from all officer and/or director positions held at any member of the Company Group, and at the Board’s request, the Executive will execute any documents reasonably necessary to
reflect the resignations. 
 11. Miscellaneous Provisions. 

(a) No Duty to Mitigate. The Executive will not be required to mitigate the amount of any payment contemplated by this Agreement, nor
will any payment be reduced by any earnings that the Executive may receive from any other source except as specified in Section 3(e). 

(b) Waiver; Amendment. No provision of this Agreement will be modified, waived or discharged unless the modification, waiver or
discharge is agreed to in writing and signed by an authorized officer of the Company (other than the Executive) and by the Executive. No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by
the other party will be considered a waiver of any other condition or provision or of the same condition or provision at another time. 

(c) Headings. All captions and section headings used in this Agreement are for convenient reference only and do not form a part of this
Agreement. 
 (d) Entire Agreement. This Agreement constitutes the entire agreement of the parties and supersedes in their entirety
all prior representations, understandings, undertakings or agreements (whether oral or written and whether expressed or implied) of the parties with respect to the subject matter of this Agreement, including, for the avoidance of doubt, any other
employment letter or agreement, change in control severance agreement, severance policy or program, or Equity Award agreement. 
 (e)
Choice of Law. This Agreement will be governed by the laws of the State of New York without regard to New York’s conflicts of law rules that may result in the application of the laws of any jurisdiction other than New York. The Executive
hereby expressly consents to the personal and exclusive jurisdiction and venue of the state and federal courts located in New York for any lawsuit filed against the Executive by any member of the Company Group. 

  
 10 

 (f) Severability. The invalidity or unenforceability of any provision or provisions
of this Agreement will not affect the validity or enforceability of any other provision of this Agreement, which will remain in full force and effect. 

(g) Withholding. All payments and benefits under this Agreement will be paid less applicable withholding taxes. The Company is
authorized to withhold from any payments or benefits all federal, state, local, and/or foreign taxes required to be withheld from the payments or benefits and make any other required payroll deductions. No member of the Company Group will pay the
Executive’s taxes arising from or relating to any payments or benefits under this Agreement. 
 (h) Counterparts. This Agreement
may be executed in counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 

[Signature page follows.] 

  
 11 

 By its signature below, each of the parties signifies its acceptance of the terms of this
Agreement, in the case of the Company by its duly authorized officer. 
  

							
	COMPANY	 		 	THORNE HEALTHTECH, INC.
				
		 		 	By:	 	 
				
		 		 	Title:	 	 
				
		 		 	Date:	 	 
			
	EXECUTIVE	 		 	  

		 		 	Thomas P. McKenna
				
		 		 	Date:	 	 

 [Signature page to Change in Control Severance Agreement] 

  
 12EX-10.26

 Exhibit 10.26 

NOMINATING, OBSERVER AND SECONDMENT AGREEMENT 

THIS NOMINATING, OBSERVER AND SECONDMENT AGREEMENT (this “Agreement”), dated as of [•], 2021, is by and between Thorne
HealthTech, Inc., a Delaware corporation (the “Company”), Kirin Holding Company, Limited (“Kirin”) and Mitsui & Co., Ltd. (“Mitsui”, and together with Kirin, the
“Stockholders” and each a “Stockholder”). 
 WHEREAS, on July 16, 2021 the Company publicly
filed with the U.S. Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended, a registration statement on Form S-1 relating to the IPO of shares of Common
Stock of the Company; 
 WHEREAS, pursuant to the Company’s Fourth Amended and Restated Stockholder Agreement dated July 5,
2018 (the “Stockholder Agreement”), each of Kirin and Mitsui has appointed two members of the Board of Directors of the Company; 

WHEREAS, the Stockholder Agreement will terminate in accordance with its terms upon the closing of the IPO; 

WHEREAS, each of Kirin and Mitsui currently owns or beneficially owns shares of Common Stock of the Company; and 

WHEREAS, the Company and each of Kirin and Mitsui desire to, amongst other things, provide for the nomination of an appointee of Kirin
and an appointee of Mitsui to the Board of Directors for election and re-election to the Board of Directors following the termination of the Stockholder Agreement and after the Company has completed the IPO.

 NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties
hereto, intending to be legally bound, hereby agree as follows: 
 1. Definitions. As used in this Agreement, the following terms
shall have the following respective meanings: 
 (a) “Affiliate” has the meaning given to that term in Rule 12b-2 under the Securities Exchange Act of 1934, as amended. 
 (b) “Board of
Directors” means the Board of Directors of the Company. 
 (c) “Bylaws” means the Bylaws of the Company, as
may be amended, restated or otherwise modified from time to time. 
 (d) “Common Stock” means shares of the
Company’s Common Stock, par value $0.01 per share. 
 (e) “Election Meeting” means any annual or special meeting
of the Company’s stockholders at which directors are to be elected. 
 (f) “Governing Documents” means the
Company’s certificate of incorporation, bylaws, or similar governing documents. 

 (g) “IPO” means the Company’s first underwritten public
offering of its Common Stock under the Securities Act of 1933, as amended. 
 (h) “Necessary Action” means, with
respect to a specified result, all commercially reasonable actions, to the fullest extent permitted by applicable law, necessary to cause such result, including, without limitation: (a) voting or providing a written consent or proxy with
respect to the Company’s Common Stock; (b) causing the adoption of amendments to the Governing Documents; (c) executing agreements and instruments; and (d) making, or causing to be made, with governmental, administrative or
regulatory authorities, all filings, registrations or similar actions that are required to achieve such result. 
 (i)
“Subsidiary” means, with respect to the Company, without duplication, any corporation, limited liability company, partnership, association, other business entity, or joint venture or joint venture arrangement, of which (a) if a
corporation, at least fifty percent (50%) of the total voting power of the capital stock of such corporation entitled to vote (without regard to the occurrence of any contingency) in the election of directors, managers, or trustees thereof is at the
time in question owned or controlled, directly or indirectly, by the Company or one or more of the other Subsidiaries of the Company or a combination thereof, or (b) if a limited liability company, partnership, association, other business
entity (other than a corporation), or joint venture or joint venture arrangement, at least fifty percent (50%) of the membership, partnership or other ownership interests or units thereof are at the time owned or controlled, directly or indirectly,
by the Company or one or more Subsidiaries of the Company or a combination thereof, and for this purpose, a specified person or persons shall be deemed to own a majority ownership interest in such a business entity (other than a corporation) if the
Company or its direct or indirect Subsidiaries are allocated a majority of such business entity’s gains or losses, or control any managing member, managing director or general partner of such business entity (other than a corporation). 

(j) “Tecton” means Tecton, LLC. 

2. Kirin Board Representation. 

(a) Resignation. Kirin shall cause one of its current nominees appointed to the Board of Directors to resign prior to the
closing of the IPO. 
 (b) Nomination. Subject at all times to Sections 2(c) and 9(m) herein, as long as Kirin
continues to hold at least 50% of the shares of Common Stock Kirin holds as of the date of this Agreement (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares of Common Stock) (the
“Kirin Nomination Requirement”) the Company shall take Necessary Action to support the nomination of, and cause the Board of Directors (or the nominating committee thereof) to recommend and include in the slate of nominees
recommended to the Company’s stockholders for election as directors of the Company at each Election Meeting, one (1) person designated at any time and from time to time by Kirin (the “Kirin Designee”) to the Board of
Directors as a director; provided that, the Company shall have no obligation to support the nomination of or cause the Board of Directors to include in the slate of nominees recommended to the Company’s stockholders for election as
directors of the Company a Kirin Designee if Kirin already has a Kirin Designee serving as a director on the Board of Directors at the time of the Election Meeting and the term(s) of such Kirin Designee as a director on the Board of Directors does
not expire at such Election Meeting. Kirin will provide the Company, in writing, the information about any Kirin Designee that is reasonably required by applicable law promptly after the Company requests such information from Kirin, and will cause
any Kirin Designee to submit on a timely basis to the Company a completed and executed questionnaire in the form that the Company provides to its outside directors generally. 

 (c) Nominee Objection. Notwithstanding the provisions of Section 2(b),
Kirin shall not be entitled to designate any person as a nominee to the Board of Directors if a majority of the members of the Board of Directors who were not nominated by, and are not affiliated with, Kirin or Mitsui (the “Disinterested
Directors”) reasonably and in good faith determines, after consultation with the Company’s outside legal counsel, that such person would not be qualified to serve as a director of the Company under any applicable law (including
requirements of fiduciary duties under applicable law), rule or regulation, rule of the stock exchange on which the Company’s shares are listed, the Bylaws or any Company corporate governance policies or guidelines previously approved by the
Board of Directors. The Company shall notify Kirin as soon as reasonably practicable of any objection to a Kirin Designee pursuant to this Section 2(c) as to enable Kirin to propose a replacement Kirin Designee in accordance with the terms of
this Agreement. Kirin shall use reasonable best efforts to propose a Kirin Designee sufficiently in advance of the date on which the proxy materials are to be mailed by the Company in connection with an Election Meeting to allow for inclusion of a
Kirin Designee in such proxy materials. 
 (d) Nominee Replacement Requirements. For so long as Kirin meets the Kirin
Nomination Requirement, in the event that a Kirin Designee resigns from his or her seat on the Board of Directors or is removed or otherwise fails to become or ceases to be a director for any reason, the vacancy will be filled by the election or
appointment of another Kirin Designee nominated by Kirin as soon as reasonably practicable in compliance with applicable laws, rules and regulations and the terms of this Agreement (the “Kirin Successor Designee”). Kirin will
provide the Company, in writing, the information about any Kirin Successor Designee that is reasonably required by applicable law promptly after the Company requests such information from Kirin, and will cause any Kirin Successor Designee to submit
on a timely basis to the Company a completed and executed questionnaire in the form that the Company provides to its outside directors generally. Any Kirin Successor Designee must (a) be qualified to serve as a member of the Board of Directors
under all applicable corporate governance policies or guidelines of the Company and the Board of Directors and applicable legal, regulatory and stock market requirements; (b) meet the independence requirements with respect to the Company of the
listing rules of The NASDAQ Stock Market LLC or any successor thereto; and (c) be reasonably acceptable to the members of the Board of Directors in the good faith exercise of their fiduciary duties. If any Kirin Successor Designee does not meet
the requirements of this Section 2(d), then Kirin may designate another person as the Kirin Successor Designee until an acceptable designee is found. Upon becoming a member of the Board of Directors, the Kirin Successor Designee will succeed to
all of the rights and privileges, and will be bound by the terms and conditions, of the Kirin Designee under this Agreement. 
 (e)
Conditions. Kirin understands that, as a condition to the appointment of the Kirin Designee, the Company may require the Kirin Designee to agree in writing, during the term of any service as a director of the Company, to (a) comply with
all policies, procedures, processes, codes, rules, standards and guidelines applicable to all non-employee members of the Board of Directors, including, without limitation, the Company’s code of conduct,
insider trading policy, Regulation FD policy, related party transactions policy and corporate governance guidelines, in each case as previously approved by the Board of Directors and as amended from time to time; and (b) keep confidential and
not publicly disclose discussions and matters considered in meetings of the Board of Directors and its committees or other confidential information of the Company that the Kirin Designee receives from the Company, unless previously disclosed
publicly by the Company, and Kirin shall cause the Kirin Designee to comply with any such agreement; provided, that notwithstanding anything herein to the contrary, the Kirin Designee may, to the extent not prohibited by antitrust,
competition or any other applicable law, disclose confidential information (i) to its or Kirin’s attorneys, accountants, and other professionals (the “Kirin Agents”) to the extent necessary to obtain their services
in connection with monitoring Kirin’s investment or interest in the Company, provided such persons are subject to professional duties of confidentiality and non-use or agree to be bound by confidentiality
and non-use restrictions with respect to the confidential information of the Company at least as restrictive as those 

 
applicable to the Kirin Designee and (ii) to employees of Kirin (the “Kirin Employees”) to the extent necessary to monitor Kirin’s investment or interest in the
Company, provided that the Kirin Designee informs such person that such information is confidential and such person agrees to be bound by confidentiality and non-use restrictions with respect to the confidential information at least as restrictive
as those applicable to the Kirin Designee. Furthermore, Kirin (x) agrees that it shall be liable for any damage, loss or liability arising from disclosure of Company confidential information by Kirin Agents and Kirin Employees and
(y) agrees not to use the confidential information in a manner that would negatively impact the Company. 
 (f)
Committees. Subject to applicable laws and stock exchange regulations, for so long as Kirin meets the Kirin Nomination Requirement, the Board of Directors will take Necessary Action to appoint the Kirin Designee to each standing committee of
the Board of Directors, except for the Audit Committee. 
 (g) Initial Director. The initial Kirin Designee shall be Toru
Yoshimura who shall initially be elected as a Class III director with a term expiring at the Company’s Annual Meeting of Stockholders in respect of the fiscal year ending December 31, 2024. 

3. Mitsui Board Representation. 

(a) Resignation. Mitsui shall cause one of its current nominees appointed to the Board of Directors to resign prior to the
closing of the IPO. 
 (b) Nomination. Subject at all times to Sections 3(c) and 9(m) herein, as long as Mitsui
continues to hold at least 50% of the shares of Common Stock Mitsui holds as of the date of this Agreement (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares of Common Stock) (the
“Mitsui Nomination Requirement”) the Company shall take Necessary Action to support the nomination of, and cause the Board of Directors (or the nominating committee thereof) to recommend and include in the slate of nominees
recommended to the Company’s stockholders for election as directors of the Company at each Election Meeting, one (1) person designated at any time and from time to time by Mitsui (the “Mitsui Designee”) to the Board of
Directors as a director; provided that, the Company shall have no obligation to support the nomination of or cause the Board of Directors to include in the slate of nominees recommended to the Company’s stockholders for election as
directors of the Company a Mitsui Designee if Mitsui already has a Mitsui Designee serving as a director on the Board of Directors at the time of the Election Meeting and the term(s) of such Mitsui Designee as a director on the Board of Directors
does not expire at such Election Meeting. Mitsui will provide the Company, in writing, the information about any Mitsui Designee that is reasonably required by applicable law promptly after the Company requests such information from Mitsui, and will
cause any Mitsui Designee to submit on a timely basis to the Company a completed and executed questionnaire in the form that the Company provides to its outside directors generally. 

(c) Nominee Objection. Notwithstanding the provisions of Section 3(b), Mitsui shall not be entitled to designate any person
as a nominee to the Board of Directors if a majority of the Disinterested Directors reasonably and in good faith determines, after consultation with the Company’s outside legal counsel, that such person would not be qualified to serve as a
director of the Company under any applicable law (including requirements of fiduciary duties under applicable law), rule or regulation, rule of the stock exchange on which the Company’s shares of Common Stock are listed, the Bylaws or any
Company corporate governance policies or guidelines previously approved by the Board of Directors. The Company shall notify Mitsui as soon as reasonably practicable of any objection to a Mitsui Designee pursuant to this Section 3(c) as to
enable Mitsui to propose a replacement Mitsui Designee in accordance with the terms of this Agreement. Mitsui shall use reasonable best efforts to propose a Mitsui Designee sufficiently in advance of the date on which the proxy materials are to be
mailed by the Company in connection with an Election Meeting to allow for inclusion of a Mitsui Designee in such proxy materials. 

 (d) Nominee Replacement Requirements. For so long as Mitsui meets the Mitsui
Nomination Requirement, in the event that a Mitsui Designee resigns from his or her seat on the Board of Directors or is removed or otherwise fails to become or ceases to be a director for any reason, the vacancy will be filled by the election or
appointment of another Mitsui Designee nominated by Mitsui as soon as reasonably practicable in compliance with applicable laws, rules and regulations and the terms of this Agreement (the “Mitsui Successor Designee”). Mitsui will
provide the Company, in writing, the information about any Mitsui Successor Designee that is reasonably required by applicable law promptly after the Company requests such information from Mitsui, and will cause any Mitsui Successor Designee to
submit on a timely basis to the Company a completed and executed questionnaire in the form that the Company provides to its outside directors generally. Any Mitsui Successor Designee must (a) be qualified to serve as a member of the Board of
Directors under all applicable corporate governance policies or guidelines of the Company and the Board of Directors and applicable legal, regulatory and stock market requirements; (b) meet the independence requirements with respect to the
Company of the listing rules of The NASDAQ Stock Market LLC or any successor thereto; and (c) be reasonably acceptable to the members of the Board of Directors in the good faith exercise of their fiduciary duties. If any Mitsui Successor
Designee does not meet the requirements of this Section 3(d), then Mitsui may designate another person as the Mitsui Successor Designee until an acceptable designee is found. Upon becoming a member of the Board of Directors, the Mitsui
Successor Designee will succeed to all of the rights and privileges, and will be bound by the terms and conditions, of the Mitsui Designee under this Agreement. 

(e) Conditions. Mitsui understands that, as a condition to the appointment of the Mitsui Designee, the Company may require the
Mitsui Designee to agree in writing, during the term of any service as a director of the Company, to (a) comply with all policies, procedures, processes, codes, rules, standards and guidelines applicable to all
non-employee members of the Board of Directors, including, without limitation, the Company’s code of conduct, insider trading policy, Regulation FD policy, related party transactions policy and corporate
governance guidelines, in each case as previously approved by the Board of Directors and as amended from time to time; and (b) keep confidential and not publicly disclose discussions and matters considered in meetings of the Board of Directors
and its committees or other confidential information of the Company that the Mitsui Designee receives from the Company, unless previously disclosed publicly by the Company, and Mitsui shall cause the Mitsui Designee to comply with any such
agreement; provided, that notwithstanding anything herein to the contrary, the Mitsui Designee may, to the extent not prohibited by antitrust, competition or any other applicable law, disclose confidential information (i) to its or
Mitsui’s attorneys, accountants, and other professionals (the “Mitsui Agents”) to the extent necessary to obtain their services in connection with monitoring Mitsui’s investment or interest in the Company, provided
such persons are subject to professional duties of confidentiality and non-use or agree to be bound by confidentiality and non-use restrictions with respect to the
confidential information of the Company at least as restrictive as those applicable to the Mitsui Designee and (ii) to directors and employees of Mitsui (the “Mitsui Employees”) (which, for the avoidance of doubt, shall
include directors and employees of Mitsui’s subsidiaries, including Mitsui & Co. (U.S.A.), Inc.) to the extent necessary to monitor Mitsui’s investment or interest in the Company, provided that the Mitsui Designee informs such
person that such information is confidential and such person agrees to be bound by confidentiality and non-use restrictions with respect to the confidential information at least as restrictive as those applicable to the Mitsui Designee. Furthermore,
Mitsui (x) agrees that it shall be liable for any damage, loss or liability arising from disclosure of Company confidential information by Mitsui Agents and Mitsui Employees and (y) agrees not to use the confidential information in a
manner that would negatively impact the Company. 

 (f) Committees. Subject to applicable laws and stock exchange regulations, for
so long as Mitsui meets the Nomination Requirement, the Board of Directors will take Necessary Action to appoint the Mitsui Designee to each standing or special committee of the Board of Directors, except for the Audit Committee. 

(g) Initial Director. The initial Mitsui Designee shall be Toshitaka Inuzuka who shall initially be elected as a Class III
director with a term expiring at the Company’s Annual Meeting of Stockholders in respect of the fiscal year ending December 31, 2024. 

4. Observer Rights. 

(a) For so long as Kirin meets the Kirin Nomination Requirement, (x) the Company shall cause each of its Subsidiaries to invite a
representative of Kirin to attend all meetings of its board of directors (or applicable governing body) (or any committee meetings of the foregoing), and (y) the Company shall use its commercially reasonable efforts to cause each of its
controlled Affiliates (including Tecton) to invite one (1) representative of Kirin to attend all meetings of its board of directors (or applicable governing body) (or any committees of the foregoing) in a nonvoting observer capacity and, in
this respect, shall give copies of all notices, minutes, consents, and other materials that it provides to directors (or other members of the applicable governing body) at the same time and in the same manner as provided to such directors (or other
members of the applicable governing body); provided, however, that each such representative shall agree in writing to a nondisclosure agreement in a reasonable and customary form approved by the Company (provided any such agreement shall be
in substantially the same form and no more restrictive than any similar agreement signed by the other directors or other members of the applicable governing body and otherwise consistent with the conditions set forth in Section 2(e)), which
shall provide that such representative will hold in confidence and trust all information so provided; and provided, further, that each Subsidiary and controlled Affiliate may withhold any information and exclude such representative from any meeting
or portion thereof if access to such information or attendance at such meeting reasonably would, after consultation with the Company’s (or such controlled Affiliate’s) outside legal counsel, adversely affect the attorney-client privilege
between the respective Subsidiary or controlled Affiliate and its counsel or result in disclosure of trade secrets or a conflict of interest, as determined in good faith by a majority of the members of such Subsidiary’s board of directors who
were not nominated by, and are not affiliated with, Kirin or Mitsui, or a majority of the members the board of directors (or applicable governing body) of such controlled Affiliate who were not nominated by, and are not affiliated with, Kirin or
Mitsui, or the Disinterested Directors. 
 (b) For so long as Mitsui meets the Mitsui Nomination Requirement, (x) the Company
shall cause each of its Subsidiaries to invite a representative of Mitsui to attend all meetings of its board of directors (or applicable governing body) (or any committee meetings of the foregoing), and (y) the Company shall use its
commercially reasonable efforts to cause each of its controlled Affiliates (including Tecton) to invite one (1) representative of Mitsui to attend all meetings of its board of directors (or applicable governing body) (or any committees of the
foregoing) in a nonvoting observer capacity and, in this respect, shall give copies of all notices, minutes, consents, and other materials that it provides to directors (or other members of the applicable governing body) at the same time and in the
same manner as provided to such directors (or other members of the applicable governing body and otherwise consistent with the conditions set forth in Section 3(e)); provided, however, that each such representative shall agree in writing
to a nondisclosure agreement in a reasonable and customary form approved by the Company (provided any such agreement shall be in substantially the same form and no more restrictive than any similar agreement signed by the other directors or other
members of the applicable governing body), which shall provide that such representative will hold in confidence and trust all information so provided; and provided, further, that each Subsidiary and controlled Affiliate may withhold any information
and exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting reasonably would, after 

 
consultation with the Company’s (or Tecton’s) outside legal counsel, adversely affect the attorney-client privilege between the respective Subsidiary or controlled Affiliate and its
counsel or result in disclosure of trade secrets or a conflict of interest, as determined in good faith by a majority of the members of such Subsidiary’s board of directors who were not nominated by, and are not affiliated with, Kirin or
Mitsui, or a majority of the members the board of directors (or applicable governing body) of such controlled Affiliate who were not nominated by, and are not affiliated with, Kirin or Mitsui, or the Disinterested Directors. 

5. Secondment. 
 (a)
For so long as Kirin meets the Kirin Nomination Requirement, Kirin, or an Affiliate thereof, shall have the right to second one employee to serve as secondee to the Company or any of its Subsidiaries, with the rights and on the terms set forth in a
secondment agreement between Kirin, the Company and the applicable secondee in a form to be reasonably agreed by such parties (which shall include reasonable and customary provisions with respect to confidentiality (including limiting the
information that such secondee may disclose to Kirin), conflicts of interest and assignment of intellectual property rights no less restrictive than the corresponding provisions of agreements executed by employees of the Company). If for immigration
status reasons a designated secondee of Kirin is unable to be employed by the Company or its subsidiaries, such secondee shall remain an employee of Kirin and Kirin, the Company and applicable secondee shall enter into a service agreement whereby
such person will provide services to the Company on terms similar to the secondment agreement. 
 (b) For so long as Mitsui meets the
Mitsui Nomination Requirement, Mitsui, or an Affiliate thereof, shall have the right to second one employee to serve as secondee to the Company or any of its Subsidiaries, with the rights and on the terms set forth in a secondment agreement between
Mitsui, the Company and the applicable secondee in a form to be reasonably agreed by such parties (which shall include reasonable and customary provisions with respect to confidentiality (including limiting the information that such secondee may
disclose to Mitsui), conflicts of interest and assignment of intellectual property rights no less restrictive than the corresponding provisions of agreements executed by employees of the Company). If for immigration status reasons a designated
secondee of Mitsui is unable to be employed by the Company or its subsidiaries, such secondee shall remain an employee of Mitsui and Mitsui, the Company and applicable secondee shall enter into a service agreement whereby such person will provide
services to the Company on terms similar to the secondment agreement. 
 6. D&O Insurance; Indemnification. 

(a) D&O Insurance. The Company shall include any Kirin Designee, Mitsui Designee or any of their successors, appointed to the
Board of Directors in its Directors and Officers liability insurance policy and will use commercially reasonable efforts to cause such insurance policy to be maintained until such time as the Board of Directors, including the Kirin Designee and the
Mitsui Designee, determines that such insurance should be discontinued. 
 (b) Indemnification. The Company shall provide
customary indemnification to the Kirin Designee, Mitsui Designee or any of their successors, appointed to the Board of Directors on terms to be agreed by the parties and no less favorable than indemnification agreements entered into between the
Company and each of its non-employee directors. 

 7. Access to Information. 

(a) For so long as Kirin has the right to designate a director for nomination under this Agreement and subject to the confidentiality
obligations set forth in Section 8 below, the Company shall, and shall cause its Subsidiaries to, permit Kirin and its respective designated representatives, at reasonable times and upon reasonable prior notice to the Company, to review the
books and records of the Company or any of such Subsidiaries and to discuss the affairs, finances and condition of the Company or any of such Subsidiaries with the officers of the Company or any such Subsidiary to the extent necessary for Kirin to
comply with accounting, law, and tax reporting requirements. For so long as Kirin has the right to designate a director for nomination under this Agreement, the Company shall, and shall cause its Subsidiaries to, provide Kirin, with copies of the non-consolidated financial statements and individual tax returns of the Company and its Subsidiaries, and such other information that is required to facilitate Kirin’s reporting of passive income (including
capital gains) with respect to its investment in Thorne. 
 (b) For so long as Mitsui has the right to designate a director for
nomination under this Agreement and subject to the confidentiality obligations set forth in Section 8 below, the Company shall, and shall cause its Subsidiaries to, permit Mitsui and its respective designated representatives, at reasonable
times and upon reasonable prior notice to the Company, to review the books and records of the Company or any of such Subsidiaries and to discuss the affairs, finances and condition of the Company or any of such Subsidiaries with the officers of the
Company or any such Subsidiary to the extent necessary for Mitsui to comply with accounting, law, and tax reporting requirements. For so long as Mitsui has the right to designate a director for nomination under this Agreement, the Company shall, and
shall cause its Subsidiaries to, provide Mitsui, with copies of the non-consolidated financial statements and individual tax returns of the Company and its Subsidiaries, and such other information that is
required to facilitate Mitsui’s reporting of passive income (including capital gains) with respect to its investment in Thorne. 
 8.
Confidentiality. Each Stockholder agrees to: (a) hold in confidence and trust, and not disclose, any nonpublic, proprietary or confidential information of the Company and its Subsidiaries (the “Confidential Information”)
and (b) use its reasonable best efforts to ensure that any third party to which it provides such Confidential Information pursuant to this Section 8 shall hold such information in confidence and trust and use such
Confidential Information solely for the benefit of the Company and its Subsidiaries; provided, that a Stockholder may disclose confidential information (i) to Kirin Agents or Mitsui Agents, as applicable, to the extent necessary to
obtain their services in connection with monitoring its investment or interest in the Company, provided such persons are subject to professional duties of confidentiality and non-use or agree to be
bound by confidentiality and non-use restrictions with respect to the Confidential Information at least as restrictive as those set forth in this Section 8, (ii) to any Kirin
Employees or Mitsui Employees, as applicable, to the extent necessary to monitor their investment or interest in the Company, provided that such Stockholder informs such Person that such information is confidential and such Person agrees to be bound
by confidentiality and non-use restrictions with respect to the confidential information at least as restrictive as those set forth in this Section 8, or (iii) to the extent
required by law or regulation (including relevant securities laws and stock exchange listing standards, rules or requirements); provided, that in connection with any disclosure required by law, the Stockholder required to make such disclosure shall
to the extent legally permissible provide prior written notice of such required disclosure to the Company and shall take all reasonable and lawful actions to avoid and/or minimize the extent of such disclosure as may be reasonably requested by the
Company. Furthermore, each Stockholder (x) agrees that it shall be liable for any damage, loss or liability arising from disclosure of Company confidential information by such Stockholder to its respective agents and employees and
(y) agrees not to use the confidential information in a manner that would negatively impact the Company. Each Stockholder’s obligations under this Agreement shall be several and not joint. 

9. Miscellaneous. 

(a) Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of
Delaware, without giving effect to its principles of conflicts of laws. 

 (b) Certain Adjustments. Subject to Section 9(m) below, the provisions of
this Agreement shall apply to the full extent set forth herein with respect to any and all shares of capital stock of the Company or any successor or assign of the Company (whether by merger, consolidation, sale of assets or otherwise) that may be
issued in respect of, in exchange for, or in substitution for the shares of Common Stock, by combination, recapitalization, reclassification, merger, consolidation or otherwise and the term “Common Stock” shall include all such other
securities. In the event of any change in the capitalization of the Company, as a result of any stock split, stock dividend or stock combination or otherwise, the provisions of this Agreement shall be appropriately adjusted. 

(c) Enforcement. The parties expressly agree that the provisions of this Agreement may be specifically enforced against each of
the parties hereto in any court of competent jurisdiction. 
 (d) Successors and Assigns. Except as otherwise provided herein,
the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. 

(e) Entire Agreement. This Agreement and the Bylaws constitutes the full and entire understanding and agreement between the
parties with regard to the subject matter hereof and supersedes all prior oral or written (and all contemporaneous oral) agreements or understandings with respect to the subject matter hereof. 

(f) All notices required or permitted under this Agreement must be in writing and sent to the address or email identified below. Notices
must be given: (a) by personal delivery, with receipt acknowledged; (b) by email followed by hard copy delivered by the methods under clause (c) or (d); (c) by prepaid certified or registered mail, return receipt requested; or
(d) by prepaid reputable overnight delivery service. Notices shall be effective upon receipt. Either party may change its notice address by providing the other party written notice of such change. Notices shall be delivered as follows: 

 

			
	If to Kirin:	  	[•]
		
	If to Mitsui:	  	[•]
		
	If to the Company:	  	 Thorne HealthTech, Inc.
 152 West 57th Street
 New York, New York 10019

Attention: Paul Jacobson
 Email:
pjacobson@thorne.com

		
	with a copy (which copy shall not constitute notice) to:	  	 Wilson Sonsini Goodrich and Rosati, Professional Corporation

650 Page Mill Road
 Palo Alto, California 94063

Attention: Philip Oettinger
 Email:
poettinger@wsgr.com

 (g) Delays or Omissions. No delay or omission to exercise any right, power or
remedy accruing to either Kirin or Mitsui hereto upon any breach or default of the Company under this Agreement, shall impair any such right, power or remedy of Kirin or Mitsui nor shall it be construed to be a waiver of any such breach or default,
or an acquiescence therein, or of or in any similar breach or default thereunder occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default therefore or thereafter occurring. Any waiver, permit,
consent or approval of any kind or character on the part of either Kirin or Mitsui of any breach or default of the Company under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, in each case,
must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

(h) Counterparts. This Agreement may be executed in any number of counterparts (including by facsimile or other electronic
means), each of which may be executed by less than all of the parties hereto, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. 

(i) Severability. If any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 (j) Amendments and Waivers.
The provisions of this Agreement may be amended at any time and from time to time, and particular provisions of this Agreement may be waived or modified, with and only with an agreement or consent in writing signed by the Company, Kirin and Mitsui.
Notwithstanding the above, Sections 2, 4(a) and 5(a) may only be amended with and only with an agreement or consent in writing signed by the Company and Kirin; and Sections 3, 4(b) and 5(b) may only be amended with and only with an agreement or
consent in writing signed by the Company and Mitsui. 
 (k) Jurisdiction. The parties hereto irrevocably submit, in any legal
action or proceeding relating to this Agreement, to the jurisdiction of the courts of the United States located in the State of Delaware or in any Delaware state court and consent that any such action or proceeding may be brought in such courts and
waive any objection that they may now or hereafter have to the venue of such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient forum. 

(l) Further Assurances. The parties agree to use their best efforts and act in good faith in carrying out their obligations under
this Agreement. The parties also agree, without further consideration, to execute such further instruments and to take such further actions as may be necessary or desirable to carry out the purposes and intent of this Agreement. 

(m) Termination. This Agreement, other than with respect to the obligations set forth in Sections 2(b), 2(e), 3(b), 3(e), 8 and 9
of this Agreement, shall automatically terminate upon the later of (i) when Kirin no longer meets the Kirin Nomination Requirement, or (ii) Mitsui no longer meets the Mitsui Nomination Requirement. This Agreement may be terminated with
respect to Kirin’s rights by written agreement between the Company and Kirin. This Agreement may be terminated with respect to Mitsui’s rights by written agreement between the Company and Mitsui. 

[Remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, each of the parties hereto has executed this Nominating, Observer and
Secondment Agreement as of the date first above written. 
  

			
	THORNE HEALTHTECH, INC.
		
	By: 	 	              

	Name:	 	
	Title:	 	
	
	KIRIN HOLDING COMPANY, LIMITED
		
	By: 	 	              

	Name:	 	
	Title:	 	
	
	MITSUI & CO., LTD.
		
	By: 	 	              

	Name:	 	
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}]]